Member Info for TorquayFan

I think Tosh was fairly well known on LSE for years before some of you Guys were around and I am fairly sure, that he is not a Woman. IMO. I also see some difference in the style of writing - have your fun . . . no problem. On this I disagree with Inan too - that's no problem either.

Was it you Ruck or you RW that reported (or not) the posts that were removed ? There was a bit of 'sharp' in the reply to HW but whoever did report it, if at all, might 'fess up' don't you think ?

I think we should ask Admin to let us know routinely on here, who IS reporting each post as it occurs.

AIMHO

No I don't. As you well know.
I've never thought HW was T.
So if HW says she is a woman that's it for me.

Sorry - missed that. In which case you ain't Tosh then !
I must keep up. ATB

Yes Maggie, of course I know that - but I wondered if you were disclosing that you are a Lady yourself. That would be good, we are a bit short of the fair sex on this BB. ATB

I doubt that anyone reported the posts ? But if so, fess up !

If I remember, the reply to your post was a little 'sharp' but nothing untoward. Maybe Admin noticed the 'sharp' without any prompt but the posts should not have been deleted IMO. I protested to Admin but got no reply.
Never mind - the discussion is back on the BB so all's well.

You posted - ''But this lady is not for turning''. Is that just a turn of phrase ?

GLA

News may arrive this week even though CH is on his well earned break. Who knows ?

Listed by Berm and Ray P a few days ago . . .

1) SCIB1 IND
2) SCIB1 CRO
3) Confirmation of study centres and investigators for SCIB1
4) SCIB1 trial to appear on Clinical Trials Register
5) Confirmation on delivery method / final make up for SCIB2
6) Confirmation Modi1 manufacture complete
7) ModI1 CTA (before year end)

GLA

I've protested about the removal of that Inan post - which I thought - explained it to you ok.

Rest your case maybe ?

C7 well done. Of course it's a different Internet in Thailand. Not so. Tks. Tks.

HW - what is your mission here ? I think Inan explained it in his way, as he does to friend or 'friend' or foe.
Inan - your post has been removed too - ??? - I thought you explained it to HW ok ? It's gone ?
Anyway HW, I still think you're not Tosh, who btw, is aptly named.

(Had tosh as a crossword clue the other day !). I mean - why would one call yourself uumm - rubbish or similar?

GLA

hTTps://investor.regeneron.com/releaseDetail.cfm?ReleaseID=1074041

hTTps://endpts.com/with-pd-1-ok-looming-regeneron-antes-100m-on-bluebird-alliance-for-next-gen-tcr-cell-therapy-pact/

Last try. (These both open on the other side). G'night all.

"Although pembrolizumab is currently the only drug with FDA approval as a tumor-agnostic therapy, ipilimumab and nivolumab illustrate the path which cancer treatment is headed: immunotherapies targeting immunological biomarkers. Immunological biomarkers allow us to determine the quality of the immune system and monitor the success of our therapies, profiling the patient’s immune system to see what is “broken.” Checkpoint inhibitors in particular have received their many approvals using a traditional tumour-by-tumour clinical trial approach (one trial in melanoma, another in lung cancer, etc.).

The shift to tumour-agnostic medication, with a focus on the immunology and not the pathology is one that will take time; however, we can expect to see more approvals of drugs targeting immunological biomarkers."

hTTps://www.healthcareglobal.com/pharmaceutical/shift-tumour-agnostic-immunotherapies

And two more, usually of interest . . .

hTTp://investor.regeneron.com/releaseDetail.cfm?ReleaseID=1074041

hTTps://endpts.com/with-pd-1-ok-looming-regeneron-antes-100m-on-bluebird-alliance-for-next-gen-tcr-cell-therapy-pact/

GLA

Just for the dearth of, here's a piece showing that our collabs BioNTech, are in the games :-

''BioNTech AG ("BioNTech") and SiO2 Medical Products, Inc. ("SMP") today are announcing a common testing of SMP's high performance primary packaging container to preserve BioNTech´s mRNA vials for cancer-immunotherapy drugs. Following the completion of successful process evaluations involving leading fill-/finish-machine manufacturers, SMP and BioNTech want to explore and develop superior packaging as well as application devices manufactured by SMP for a range of BioNTech products.''

hTTps://www.prnewswire.com/news-releases/biontech-and-smp-to-evaluate-smps-next-generation-technology-for-biontech-products-300689982.html

Anf from Gooosed :-

''Eli Lilly must be seeing value in its broad-ranging research collaboration with the Dana-Farber Cancer Institute, as it’s extending the partnership for another three years. When the two first got together three years ago, the link-up was hailed as a “new kind of collaboration” between a cancer center and a large pharma company, with Dana-Farber contributing its expertise to multiple preclinical and clinical cancer programs in the hope of shortening drug development times.''

hTTps://www.fiercebiotech.com/biotech/lilly-firms-up-cancer-collaboration-dana-farber

Inside that link I noticed this :-

''While checkpoint inhibitors have proved effective in certain cancers, such as lung cancer and melanoma, they work only for a small percentage of patients. The hunt is on for ways to make these treatments more widely useful.''

hTTps://www.fiercebiotech.com/research/disarming-cancer-s-defenses-to-improve-immunotherapy

Hope these links work - I tried ! To a better week indeed C7. ATB

(or 10) in the freezer makes for a nice cool mop down for when it's over 40C !!

Enjoy your heat - in Thailand as fears grow about some Dams being over capacity already - it's bucketing down. We've now slept without the A/C for 10 days. Unusual.

Nice day all

''Hope that does indeed signal the end of the SCLP BB on LSE in its current dreadful state.''

There's admittedly not much to talk about news wise atm - but nevertheless, so far in August the glittering LSE BB shows some 68 posts and the other, NIL. No too dreadful then.

BTW C7 - where is Agema who has not been around for some time it seems ?

I hope you have a good Sunday in that heat. Phew !

As listed by Berm and Ray P a few days ago - food for Sunday thought . . .

1) SCIB1 IND
2) SCIB1 CRO
3) Confirmation of study centres and investigators for SCIB1
4) SCIB1 trial to appear on Clinical Trials Register
5) Confirmation on delivery method / final make up for SCIB2
6) Confirmation Modi1 manufacture complete
7) ModI1 CTA (before year end)

A list follows of unexpected and 'Left Field' news to come :-
?
?
?

GLA

'Dying' is a bad idea if you want to hear news of the 'inflection' point but I know what you mean.

I share your impatience as always and call on this from the mighty Berm last week, ''Scancell communicate what they can, when they can. I would also add that when it comes to communication, Richard Goodfellow was one of the most responsive and approachable CEO's I have come across. So far, Cliff Holloway appears to be following in the same vein.''

I agree that CH is spot on BUT I wish he would get 'is 'ead outa those cocktails, dust the sand of his feet and sign a whopping great deal somewhere. I mean - how hard can that be ?

GLA

RW don't knock the Baht ! B20 billion would be about £500 million ?

More than 10 times our present MCap ! That's not bad by 8.30 am tomorrow . . . LOL

E & O E. Off to watch TPL at the Pub. GLA

Excellent RP. But was that £ or $ ?

''Merck & Co’s cancer immunotherapy Keytruda has finally overtaken Bristol-Myers Squibb’s rival Opdivo in sales – and EU regulators just rejected a new use for BMS’ drug while green-lighting two new indications for its competitor'' and ''Sales of Keytruda rose 89.2% compared with last year’s Q2 to $1.67 billion''.

Can extrapolate from that 89% increase - maybe Keytruda sales this year will increase to $7-8 billion a year or more. Next year who knows ? That's a lotta dolla ! And Scancell are soon to be part of the Keytruda picture . . .

https://pharmaphorum.com/news/eu-regulators-reject-new-use-for-opdivo-as-keytruda-edges-ahead/

''quality over quantity is better.'' Agreed

Get some sleep.